A DNA vaccine encoding for TcSSP4 induces protection against acute and chronic infection in experimental Chagas...

Area of Science:

• Immunology
• Parasitology
• Vaccine Development

Background:

• Chagas disease, caused by the parasite Trypanosoma cruzi, poses a significant global health challenge.
• Current treatment options for Chagas disease are limited and often associated with toxicity.
• Developing effective vaccines against Trypanosoma cruzi is crucial for disease control.

Purpose of the Study:

• To evaluate the efficacy of a DNA vaccine encoding the amastigote-specific surface protein 4 (TcSSP4) of Trypanosoma cruzi.
• To compare the protective immune response induced by DNA vaccination versus recombinant protein immunization.
• To assess the long-term impact of vaccination on Chagas disease pathology in a murine model.

Main Methods:

• Mice were immunized with a eukaryotic expression plasmid containing the TcSSP4 cDNA or with the recombinant TcSSP4 protein.
• Immunized mice were subsequently challenged with bloodstream trypomastigotes of Trypanosoma cruzi.
• Protection was assessed by monitoring mortality rates, parasite load, and histopathological changes in heart tissue.
• Immune responses, including interferon-gamma (INF-γ) production, were analyzed.

Main Results:

• DNA vaccination with TcSSP4 cDNA conferred significant protection against Trypanosoma cruzi infection, controlling the acute phase and reducing mortality.
• Recombinant TcSSP4 protein immunization rendered mice more susceptible to infection, leading to high mortality rates.
• Gene-vaccinated animals showed no signs of myocarditis or tissue damage at 365 days post-infection, unlike control groups.
• Detection of INF-γ in sera of DNA-vaccinated mice indicated the development of a T-helper 1 (Th1) immune response.

Conclusions:

• The TcSSP4 gene is a promising candidate for developing an effective anti-Trypanosoma cruzi DNA vaccine.
• DNA vaccination strategy using TcSSP4 elicits a protective immune response against Chagas disease.
• TcSSP4 DNA vaccine prevents long-term cardiac pathology associated with Trypanosoma cruzi infection.